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The bidirectional interactions between tumor cells and the so-called “host reactive stroma” play a critical role in most of the events 
characterizing tumor progression and distant organ colonization. This review discusses critical components of tumor environment 
involved in tumor cell dissemination. More specifically, it addresses some of the experimental evidences providing that acidity of tumor 
environment facilitates local invasiveness and metastasis formation, independently from hypoxia, with which acidity may be associ-
ated. Besides, acidity renders tumor cells resistant to radiation therapy and chemotherapeutic drugs. Therefore, this review examines 
the strategies for raising the low extracellular pH of tumors that might have considerable potential in cancer therapy.
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CANCER AS A COMPLEX SCENARIO 
OF TUMOR CELLS AND AN ACTIVE STROMA
Capacity of cancer to evolve and change has been 
named “tumor progression” [1]. Biological character-
istics that define tumor progression have been exten-
sively described, although the underlying mechanisms 
remain unknown. Malignant tumor cells accumulate 
increasingly genetic alterations, generated by random 
mutational events, leading them to assume all the 
characteristics of invasive cells. In concert with this 
“genetic instability”, a key role in favouring changes 
in tumor cells is played by local host factors [2, 3]. 
Among local factors, particular attention has been 
devoted to the interactions that tumor cells establish 
with various host cells that reside in or are attracted into 
tumor environment. The bidirectional interaction be-
tween tumor cells and host cells, is recognized as cru-
cial for the decision whether tumor cells progress 
toward metastatic dissemination or remain dormant 
[4–8]. Indeed,  tumor growth and metastasis is sig-
nificantly reduced in fibroblast-deficient mice, while 
injection of wild-type fibroblasts into these mice can 
reverse this phenotype, providing a clear evidence for 
the involvement of fibroblasts in the emergence of me-
tastasis [9–11]. This type of activated cells, commonly 
identified by the expression of -smooth muscle actin 
(-SMA) and referred as “myofibroblasts” [12], was 
named cancer-associated fibroblasts (CAFs) and ac-
tively participates at all stages of metastatic cascade. 
In addition cells of monocyte/macrophage lineage 
enter into the tumor mass via blood vessels throughout 
life span of tumors, from early-stage lesions to late-
stage tumors that are invasive and metastatic, and are 
indicated as tumor-associated macrophages (TAMs) 
[13, 14]. TAMs are remarkable for the diverse activi-
ties in which they can engage on different occasions. 
Quiescent macrophages respond to immune or bac-
terial stimuli by expressing new functional activities, 
resulting in their capacity to recognize and destroy 
transformed cells. On the contrary, macrophages 
isolated from experimental and spontaneous tumors 
show a reduced level of cytotoxic activities and was 
proved to be relevant to tumor progression and mes-
tastases [15, 16]. Plasticity of both CAFs and TAMs 
may be exploited by tumor cells to elicit distinct func-
tions at different stages of tumor progression. It is also 
possible that changes expressed by these host cells 
during tumor development might be related to their 
location inside the tumor mass. Most tumors develop 
an environment characterized by low oxygen tension 
(hypoxia), elevated interstitial fluid pressure, low glu-
cose concentration and high lactate concentration. 
These changes are largely caused by a combination 
of poor tissue perfusion due to abnormal tumor vas-
culature, uncontrolled proliferation and altered energy 
metabolism [17]. 
Cells require oxygen and nutrients for their survival 
and growth. Likewise, neoplastic cells depend on near-
by capillaries for growth and once aggregates of tumor 
cells reach the diffusion limit for critical nutrients and 
oxygen, tumor cells become dormant. Indeed, some 
human tumors can remain dormant for a number 
of years at a stage where tumor cell proliferation and 
death are balanced. But once new blood vessel forma-
tion is initiated, the so-called angiogenic switch, tumor 
progression and metastasis follow [18]. The new vessel 
formation governed by a balance of pro- and anti-
angiogenenic factors is often disturbed in tumors lea-
ding to a vasculature characterized by dilated, tortuous 
and incomplete vessels. The molecular mechanisms 
causing this abnormal vascular architecture are still 
debated, but the uncontrolled vascular endothelial 
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growth factor A (VEGF-A) signalling may be a key 
contributor. VEGF-A is a strong mitogen and survival 
growth factor for vascular endothelial cells and induces 
mobilization and recruitment of endothelial precursor 
cells [19, 20]. Furthermore, VEGF-A contributes to the 
angiogenic phenotype by increasing the permeability 
of existing vessels, permitting extravasation of fibrino-
gen and clotting factors and resulting in a fibrin-rich 
stroma that supports migration of endothelial cells 
and formation of new vasculature. However, the 
uncontrolled secretion of VEGF-A results in a lower 
perfusion rates in tumors than in many normal tissues. 
Blood flow in tumors is unevenly distributed and can 
even reverse its direction in some vessels, therefore, 
regions with poor perfusion are common. These 
environmental features vary widely in different areas 
of tumors, reflecting tumor cell heterogeneity. In addi-
tion, the uncontrolled growth of tumor cells compress 
the intra-tumor lymphatic vessels. Consequently, there 
are no functional lymphatic vessels inside solid tumors, 
whereas functional lymphatic vessels are present only 
in peri-tumoral tissues [21, 22]. Both, the high perme-
ability of tumor blood vessels and the lack of functional 
lymphatics are keys contributors to the development 
of an interstitial hypertension in neoplastic tissues 
[23]. As a result, the hydrostatic and colloid osmotic 
pressures become almost equal between intravascular 
and extravascular spaces, compromising the delivery 
of nutrients as well as therapeutic agents. Since tumor 
interstitial hypertension is a reflection of global patho-
physiology of tumors, it may be used for diagnosis 
and/or prognosis. The consequent metabolic hallmark 
of tumor environment is hypoxia. Hypoxia character-
izes the microenvironment of many solid tumors and 
it has been shown to affect many biological proper-
ties of tumor cells implicated in tumor progression, 
response to therapy, including clinical outcome of pa-
tients [24–26]. The mechanism behind these effects 
is related to the induction of hypoxia-inducible factor 
(HIF) family of transcription factors. Under conditions 
of acute or chronic hypoxia, HIF-1 is stabilized, form 
a heterodimer with HIF-1, allowing this factor to bind 
a core sequence and increase transcription of target 
genes. This factor regulates many cellular processes 
including apoptosis, cell proliferation, angiogenesis 
and glucose metabolism [27, 28]. Thus, hypoxia in-
creases genetic instability, blood vessel formation and 
a switch to anaerobic metabolism.  
Hypoxia, elevated interstitial fluid pressure, low 
glucose and high lactate concentration resulting from 
a predominant anaerobic metabolism, are responsible 
of low extracellular pH (pHe) in tumor tissues. As a con-
sequence, the second metabolic hallmark of tumor 
environment is tumor acidosis.
In this review, we will discuss evidence that aci-
dity of tumor extracellular space represents a direct 
contributor to the process of tumor progression and 
that normalization of pHe could be considered a new 
strategy for tumor therapy. 
CONSEQUENCES OF TUMOR ACIDITY
In contrast to normal cells, which rely on mitochon-
drial oxidative phosphorylation to generate the energy 
needed for cellular processes, most cancer cells, 
even in the presence of sufficient oxygen to support 
mitochondrial respiration, use “aerobic glycolysis”, 
a phenomenon termed “the Warburg effect” [29, 
30]. This phenomenon was first reported by Warburg 
in the 1920s, leading to hypothesis that cancer results 
from impaired mitochondrial metabolism. Although 
the “Warburg hypothesis” has proven incorrect, 
an increased conversion of glucose to lactic acid 
in tumor cells has been continuously demonstrated 
(½ (glucose) = lactate- + H+). The clinical application 
of the imaging technique positron-emission tomog-
raphy (PET) using the glucose analog 2-(18F)-fluoro-
2-deoxy-D-glucose (FDG) tracer, demonstrated that 
most primary and metastatic human lesions express 
a high glucose uptake [31]. FDG-PET combined with 
computer tomography (PET/CT) has a high sensitivity 
and specificity for the detection of metastases of most 
epithelial cancers. A possible explanation for the 
switch to aerobic glycolysis is that proliferating tumor 
cells have important metabolic requirements beyond 
ATP, and some glucose must be diverted to macromo-
lecular precursors such as acetyl-CoA for fatty acids, 
glycolytic intermediates for nonessential amino acids 
and ribose for nucleotides. Moreover, some tumors 
possess a greater capacity to pump lactic acid and 
protons out to the extracellular space through specific 
transporters, to maintain an appropriate neutral/slight 
alkaline intracellular pH essential for cell proliferation. 
The inefficient removal of protons and lactic acid from 
the extracellular spaces, due to the poorly perfused 
tumor tissue and absence of functional lymphatic 
vessels, creates a reversed pH gradient characte-
rized by an acidic pHe and an alkaline intracellular pH 
(pHi) [32].
In vitro and in vivo studies revealed that tumor cells 
have pHi ranging from 7.12 to 7.56 (pHi of normal cells: 
6.99-7.20), and pHe of 6.2-6.9 (pHe of normal extracel-
lular space: 7.3-7.4). Degree of acidity in tumors tends 
to be associated with a poorer prognosis [33]. Indeed, 
tumor acidity contributes to aggressiveness of tumor 
cells, stimulating increased mutation rate [34]. Acute 
and chronic acidosis, hypoxia and reoxygenation injury 
all together promote DNA instability even in very small 
tumors leading to the selection of cells with additional 
genetic defects. Moreover, a minimum in pHe has been 
observed near tumor periphery, where tumor cells are 
invading normal tissues [35]. Hypoxia, also, stimulates 
invasiveness in tumor cells [27]. Could be expected 
that low extracellular pH and hypoxia always co-
localize within tumor regions, instead, there is often 
a lack of spatial correlation among these parameters. 
Potential explanations of this lack of correlation could 
be due to the enhanced glucose uptake for glycolytic 
ATP generation in conditions of high oxygen tension, 
or to the possibility that some tumor vessels carrying 
hypoxic blood, are unable to deliver adequate quan-
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tity of oxygen to the cells, but are able to carry away 
the waste products (e.g., lactic acid). Low pHe has 
shown to affect several steps of metastatic cascade. 
In some tumor cells, low pH promotes angiogenesis 
through VEGF [36] and IL-8 [37], however in other 
models of tumor cells acidosis inhibits VEGF [38]. 
Role of acidic pH in angiogenesis is still not completely 
understood. On the other hand, influence of acidity 
in invasiveness of tumor cells into host tissues is well 
demonstrated. Invasiveness is a multistep process 
based on extracellular matrix-degrading proteinases, 
such as serine and metallo-proteinases, reorganiza-
tion of cytoskeleton and an integrin-mediated for-
mation and release of focal adhesion contacts [39]. 
It has been reported that an acidic pHe may enhance 
invasion of tumor cells facilitating the redistribution 
of active cathepsin B, a lysosomal aspartic proteinase 
with acidic pH optima, to the surface of malignant cells 
[40, 41]. Acid-activated catepsins L also participate 
to amplify proteinase cascade through activation of 
urokinase-type plasminogen activator (uPA) [42]. The 
uPA system, made by uPA, two main plasminogen 
activator inhibitors (PAI-1, PAI-2) and uPA receptor 
(uPAR), is critical for tumor cell-driven degradation 
of extracellular matrix (ECM) in many steps of meta-
static cascade [43, 44]. Activation of cathepsins D and 
L in an acidic tumor environment reduce perfusion 
of tumor regions, generating angiogenesis inhibitors 
such as angiostatin [45] and endostatin [46] from pro-
teolysis of plasminogen and collagen, enhancing the 
chaotic vascular organization of tumors. Furthermore, 
acidic pH can promote the conversion of matrix me-
talloproteinases (MMPs) in their active forms. MMPs 
have long been associated with invasiveness and dis-
semination of tumor cells, due to their capacity to help 
tumor cells to cross structural barriers, inclu ding base-
ment membranes and structural components of the 
ECM, such as collagen fibers [47–49]. Degradation 
of structural components of ECM is considered es-
sential in tumor-induced angiogenesis. MMPs also 
participate in the release of cell-membrane-precursor-
forms of many growth factors. The expression of MMPs 
in tumors is regulated in a paracrine manner by growth 
factors and inflammatory cytokines secreted by tumor 
infiltrating inflammatory cells as well as tumor cells 
themselves, and a continuous cross talk between tu-
mor cells and inflammatory cells during the invasion 
process was demonstrated. Incubation of human and 
mouse melanoma cells in a low pH medium stimulate 
MMP expression and an increase in vitro invasiveness 
and in vivo metastasis formation in immunodeficient 
mice [50–53]. 
Another important component of basement mem-
brane to be degraded by tumor cells to disseminate 
are the heparan sulphate chains. Toyoshima and 
Nakajima report that heparanase has an optimal 
pH of 4.2, but a significant heparanase activity persists 
at pH 6.0–6.5, suggesting that the acidic environment 
of tumors may activate the degrading properties of tu-
mor heparanases [54]. 
More recently, two of the most important H+ trans-
porters, the ubiquitously expressed Na+/H+ exchanger 
isoform (NHE1) [55] and the plasma membrane type 
of vacuolar H+-ATPases (V-ATPases) [56] were found 
to be implicated in migration of tumor cells. NHE1 in-
fluences the formation of invadopodia, structures that 
regulate cell motility [57]. Cell motility is driven by cy-
cles of actin polymerization, integrin-mediated cell 
adhesion and acto-myosin contraction. Thus the 
moving tumor cells, in the absence of proteinases, 
make contact with collagen fibers and proceed along 
fibers [39]. V-ATPases are a family of ATP-dependent 
proton pumps particularly expressed by invasive pan-
creatic [58] and breast carcinomas [59], and inhibition 
of V-ATPases expression in hepatocarcinoma using 
siRNA abrogates invasion and metastatic diffusion 
of these tumor cells [60]. On the whole, an acidic 
condition may potentiate several proteinases critical 
for tumor cells when they detach from the primary tu-
mor, migrate into the blood, extravasate and colonize 
in distant host tissues.
Moreover, extracellular lactic acid can suppress 
tumoricidal activity of cytotoxic lymphocytes and 
natural killer cells, an effect mediated by lactate/H+ 
co-transporter that under neutral conditions remove 
lactic acid from leukocytes [61]. Acidification of the ex-
tracellular space may also influence radiation therapy 
and chemotherapy. Indeed, acidity of tumors reduce 
sensitivity of tumor cells to radiation therapy [62–64]. 
This protective effect is considered to be due to the 
decreased fraction of proliferating tumor cells [65] 
and the reduced fixation of radiation-induced DNA 
damage [66].
Extracellular acidity also confers a special re-
sistance against weakly basic drugs to tumor cells. 
It has been reported that chronic and acute sodium 
bicarbonate-induced alkalosis is able to circumvent 
this drug resistance and enhance the anti-tumor ac-
tivities of two weakly basic drugs, such as doxorubicin 
[67] and mitoxantrone [68]. These results suggest 
that induction of metabolic alkalosis using sodium 
bicarbonate can produce a net gain in the therapeutic 
index of the several chemotherapeutic agents, and 
open up the possibility that normalization of pHe may 
have a therapeutic utility.
MANIPULATION OF TUMOR ACIDIFICATION
Since acidity of tumor environment appears 
to contribute to cancer aggressiveness, chemo- and 
radiation resistance and, even, evasion of immune 
reactions, measures to normalize pHe of tumors may 
be used in tumor therapy. 
A number of researches have explored the pos-
sibility to correct the extracellular acidity of tumors. 
Studies revealed that in tumors levels of CO2 are 
higher and concentration of bicarbonate, the princi-
pal physiologic  buffer used to control pH, are lower 
than in blood or in healthy tissues [69, 70]. Therefore, 
it is possible that an increased concentration of sodium 
bicarbonate can reduce aggressiveness of tumor 
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cells. Indeed, the alkalization of melanoma-bearing 
animals by sodium bicarbonate was found to inhibit 
the development of spontaneous metastases [71]. In-
terestingly, a similar dose of bicarbonate used in these 
latter experiments has been administered chronically 
(>1 year) in patients with renal tubular acidosis [72] 
and sickle cell anemia without adverse effects [73]. 
Computer simulation used to verify the ability of so-
dium bicarbonate to increase pHe of tumors in vivo 
also indicates that the normalization of tumor acidity 
reduces invasiveness of tumor cells without altering 
the pH of blood or normal tissues [74].  
As an alternative strategy for correcting low pHe, 
several authors explored the inhibition in tumor cells 
of key pH regulators that maintain a neutral/alkaline 
intracellular pH by extruding lactate or protons [75]. 
pH regulators in tumor cells include extracellular 
forms of carbonic anhydrase (CA), Na+/HCO3- co-
transporters, Na+/H+ exchangers (NHEs), mono-
carboxylate transporters (MCTs) and the vacuolar 
H+-ATPase (V-ATPases). The raise of pHe promoted 
by these inhibitors is constantly associated with a de-
crease of intracellular pH. Acidity of pHi tends to sup-
press the efficiency of glycolysis, sustaining the raise 
of pHe [76], and may exert anti-proliferative and pro-
apoptotic effects on tumor cells themselves [77–79]. 
Consequently, pH regulators  might be considered true 
anticancer drugs. 
Two CA isozymes, CA9 and CA12, are overex-
pressed in tumor cells and their activity is associated 
with malignancy and resistance to therapy [80]. Sul-
phonamide CA inhibitors that target CA9 were found 
effective to block the growth of primary tumor and 
metastases in a mouse model of breast cancer [81]. 
Some of these compounds are in advanced preclini-
cal evaluation. V-ATPases, while originally identified 
in intracellular compartments, they have increasingly 
been shown to play essential roles in proton transport 
across the plasma membrane of a variety of cell types, 
including tumor cells [59, 76, 82]. The likely similarity 
between V-ATPase and the H+/K+ ATPase, the enzyme 
involved in proton secretion in gastric parietal cells, 
prompted the investigation of proton pump inhibitors 
(PPIs), such as omeprazole and esomeprazole, for 
inhibiting V-ATPase. When activated by acidic pHe 
of tumors, these drugs can inhibit V-ATPase by a co-
valent interaction. Both in vitro and in vivo experi-
ences indicate that non-toxic doses of PPIs, analo-
gous to those used for treatment of Zollinger-Ellison 
syndrome, exert anti-proliferative and pro-apoptotic 
effects on melanoma cells [83]. PPIs were also dem-
onstrated to inhibit growth of B-cell lymphoma cells 
transplanted into severe combined immunodeficient 
mice [77]. Knockdown of V-ATPase expression by siR-
NA in cells isolated from a human hepatocarcinoma 
markedly reduced metastatic dissemination of these 
cells [84]. Importantly, Hashioka et al report that PPIs 
have anti-inflammatory effects and decrease mono-
cytic neurotoxicity [85]. Recently, Lee et al. found that 
omeprazole exerts a cancer-preventive role against 
colitis-induced carcinogenesis, a chemopreventive 
action independent of gastric acid suppression [86]. 
Evidence that PPIs play a role in normalization of low 
pH and abrogate inflammation, renders these drugs 
suitable to target critical mechanisms involved in tumor 
progression. Moreover, clinical data provide that PPIs 
have a very low level of systemic toxicity as compared 
with standard chemotherapeutic agents. NHE is crucial 
in pH regulation and is expressed in eve ry cell type. 
There are several NHE inhibitors, structu rally related 
to amiloride and cariporide, however the diffused 
presence of NHE in many tissues and its role in crucial 
physiological processes, confers to this class of agents 
potential risk of side effects. Inhibitors of V-ATPase 
and NHE have been shown to have an additive im-
pact on intracellular pH and on thermosensitization 
[87]. Therefore, it is crucial to develop agents that 
selectively target NHE  in tumor. At the same time, 
potent, non-toxic selective MCT inhibitors are needed. 
MCTs, are overexpressed in many tumors and the 
isoform MCT1 regulates the entry and exit of lactate 
from tumor cells. The inhibition of MCT1 was found 
to induce a switch from lactate-fuelled respiration 
to glycolisis, which was accompanied by a retardation 
of tumor growth in a mouse model of lung carcinoma 
and in transplanted human colorectal carcinoma [88].
CONCLUSION
Tumor stroma manifest some degree of plasti-
city, a property controlled by tumor cells themselves. 
Indeed, tumor cells influence host stromal elements 
to produce relevant effectors that act as tumor pro-
moters. The metabolic hallmarks of this space are 
hypoxia and acidosis. We have elucidated how the 
extracellular acidity per se, may promote an aggres-
sive and metastatic phenotype in tumor cells and how 
these findings suggest the possibility of a novel and 
effective therapeutic strategy based on the control 
of tumor acidity.
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